2011 - Agendia

Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers
Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

Evidence, MammaPrint, Other

Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

PUBLICATION: Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub Read More

kevin2024-03-25T10:55:45-07:00December 2nd, 2011|Evidence, MammaPrint, Other|

The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase
The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase

Adjuvant, Evidence, MammaPrint, MINDACT

The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase

PUBLICATION: European Journal of Cancer, December 2011, Volume 47, Issue Read More

kevin2024-03-07T11:48:20-08:00December 1st, 2011|Adjuvant, Evidence, MammaPrint, MINDACT|

Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients
Gallery
Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

Adjuvant, Evidence, MammaPrint

Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

PUBLICATION: Arch Gynecol Obstet (2011) 283: 597. https://doi.org/10.1007/s00404-010-1454-9. AUTHORS: Kunz, Read More

kevin2024-03-25T10:56:57-07:00March 1st, 2011|Adjuvant, Evidence, MammaPrint|

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue
Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

Evidence, MammaPrint, Other, Validation

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

PUBLICATION: PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163. AUTHORS: Mittempergher Read More

kevin2024-03-07T11:49:23-08:00February 11th, 2011|Evidence, MammaPrint, Other, Validation|

Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.